This is a randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ITI-007 versus placebo administered orally once daily in the treatment of agitation in patients with dementia, including Alzheimer's disease.

ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of ITI-007 in the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease

Treatment Trials

Focus your search

ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease

Description

Conditions